

CABINET FOR HEALTH AND FAMILY SERVICES

Office of Medical Cannabis

(Amended at ARRS Committee)

915 KAR 2:050. Qualifying Medical Conditions.

RELATES TO: KRS Chapter 218B

STATUTORY AUTHORITY: KRS 218B.020,~~f;—KRS/~~ 218B.140(1)(c),~~f;—KRS/~~ 218B.010(26)

CERTIFICATION STATEMENT:

NECESSITY, FUNCTION, AND CONFORMITY: KRS 218B.020 charges the Cabinet for Health and Family Services with the implementation, operation, oversight, and regulation of the medicinal cannabis program established in KRS Chapter 218B. KRS 218B.140(1)(c)21 ~~requires~~~~authorizes~~ the Cabinet for Health and Family Services to promulgate administrative regulations that establish standards, procedures, or restrictions that the cabinet deems necessary to ensure the efficient, transparent, and safe operation of the medicinal cannabis program. This administrative regulation provides clarification regarding the definition of ~~qualifying medical condition~~ contained in KRS 218B.010(26).

Section 1. The Definition of ~~Qualifying Medical Condition~~.

(1) The definition of ~~qualifying medical condition~~ contained in KRS 218B.010(26) may encompass additional medical conditions if an underlying symptom of those conditions is:

(a) Expressly defined as a ~~qualifying medical condition~~ in KRS 218B.010(26); and

(b) Properly diagnosed by a medical cannabis practitioner or the medical cannabis practitioner properly confirms the diagnosis provided by another health care provider.

(2) The following list of medical conditions have been recommended for express inclusion within the definition of ~~qualifying medical condition~~ by the Kentucky Board of Physicians and Advisors and are recognized as having at least one (1) underlying symptom that is defined as a ~~qualifying medical condition~~ under KRS 218B.010(26):

- (a) Amyotrophic Lateral Sclerosis;
- (b) Parkinson's Disease;
- (c) Crohn's Disease;
- (d) Ulcerative Colitis;
- (e) Sickle Cell Anemia;
- (f) Cachexia or Wasting Syndrome;
- (g) Neuropathies;
- (h) Severe Arthritis;
- (i) Fibromyalgia;
- (j) Muscular Dystrophy;
- (k) Huntington's Disease;
- (l) Human Immunodeficiency Virus (HIV);
- (m) Acquired Immunodeficiency Syndrome (AIDS);
- (n) Glaucoma; and
- (o) Terminal Illness.

COMPILER'S NOTE: 2025 RS HB 6, enacted by the General Assembly on March 27, 2025, altered the information to be provided at the time an administrative regulation is filed. Aside from formatting changes necessary to upload the regulation into the LRC's publication application, this regulation has been published as submitted by the agency.

FILED WITH LRC: September 9, 2026

CONTACT PERSON: Krista Quarles, Policy Analyst, Office of Legislative and Regulatory Affairs, 275 East Main Street 5 W-A, Frankfort, Kentucky 40621; Phone: 502-564-7476; Fax: 502-564-7091; CHFSregs@ky.gov.